A PHASE II OPEN-LABEL MULTICENTER RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF ADJUVANT AUTOGENE CEVUMERAN PLUS ATEZOLIZUMAB AND MFOLFIRINOX VERSUS MFOLFIRINOX ALONE IN PATIENTS WITH RESECTED PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Pancreatic Ductal Adenocarcinoma
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Preoperative diagnosis of resectable PDAC tumor, as demonstrated by preoperative imaging with computed tomography (CT) scan with contrast or magnetic resonance imaging (MRI) scan per institutional standard for imaging evaluation of pancreas

You may not be eligible for this study if the following are true:

    1. Prior adjuvant, neoadjuvant, or induction treatment for pancreatic cancer, including cytotoxic chemotherapy, immunotherapy, investigational therapy, or radiation therapy
    2. Absence of spleen (due to splenectomy, splenic injury/infarctio


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.